A new publication referencing somatostatin appeared on August 22, 2026. The article, titled "Neurovascular unit-targeted therapeutic strategies in diabetic retinopathy," was published in Archivos de la Sociedad Espanola de Oftalmologia.
Somatostatin remains classified as an unapproved research compound. This entry reflects only that the publication exists as of the stated date, in the named journal, under the given title. No findings, conclusions, or efficacy data from the publication are included here.
Readers interested in the study details are encouraged to consult the original article directly through the source link provided. For broader context on somatostatin, including its regulatory status and general background, see the compound overview.